This is the one comparison in this cluster where the FDA paperwork genuinely separates the two devices. The Profound System's clearance (K161043, 2016) names cosmetic uses in its own text. Morpheus8's does not.
Profound's cleared wording is unusually specific. It reads: "the 25º Dermal handpiece and cartridge are used for percutaneous treatment of facial wrinkles, and the 75º SubQ handpiece and cartridge are used to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III as supported by long-term clinical data (6 months)." Percutaneous means through the skin. Note the skin-type limit on the cellulite claim — it covers Fitzpatrick I to III only.
The cellulite trial cited across this site is Profound's own dataset. Alexiades and colleagues, 2018, in Dermatologic Surgery: a prospective four-centre trial, 50 subjects, a single subcutaneous treatment at 67 °C for 4 seconds, graded blind by three dermatologists, with a 93% procedural success rate at six months, an average pain score of 3.74 out of 10 and no adverse events. That is the study the clearance wording refers to. Anyone quoting "93% at six months" for RF microneedling in general is quoting Profound's cellulite trial.
Morpheus8's clearance is generic electrosurgical language. Electrocoagulation and hemostasis — surgical wording for sealing tissue and stopping bleeding — in December 2019 (K192695), then coagulation or contraction of soft tissue in July 2023 (K231790). Wrinkles, cellulite, acne scars and laxity appear in neither. And almost no published study used Morpheus8: a PubMed search returns 16 records and no randomised trial, so the research clinics cite for it was generated on other manufacturers' machines.
None of this makes Profound the better treatment for you. A 510(k) clearance is mainly a finding that a device resembles one already on the market, and even Profound's indication is not proof of a lasting result. There is no published head-to-head trial of Profound against Morpheus8.
The 25º dermal handpiece has 5 electrode pairs; the 75º SubQ handpiece has 7. It is not a dense pin grid.
The pins are insulated except the distal 0.5 mm.
Temperature sensors give real-time feedback and the system works in the range 65 to 75 °C in 1 °C increments. Among the radiofrequency microneedling devices compared here, Profound is the only one whose FDA paperwork documents per-needle temperature control with a target temperature and a dwell time.
Maximum system output is 65 W and the pulse can run up to about 74 ms.
No needle depth range is published, so none is quoted here. The dermal and SubQ handpieces are distinguished by insertion angle and by which layer they are intended for.
The deepest figure in any FDA summary is 7.0 mm; "8 mm" is a 2020 marketing number combining 7 mm of needle with 1 mm of thermal profile.
Both sit inside a broader electrocoagulation and hemostasis indication. Acne scars, laxity as a standalone claim, submental fat and Fitzpatrick IV to VI for the cellulite indication are not in the clearance.
No cosmetic use is named. Above 62 mJ per pin the applicator is limited on-label to skin types I to IV.
A separate prospective study with blinded evaluators treated 24 women over 40 on the lower face and neck in a single session and reported roughly a 30% mean reduction in fine lines, wrinkles, furrows and folds and about 20% improvement in the neck silhouette, with biopsies from 12 of them.
Atrophic acne scars are the best-evidenced use of the RF microneedling class, though that evidence comes from other manufacturers' devices.
"Profound" now covers two different products with different clearances. The original Profound System (K161043) is the one with temperature sensors and the wrinkle-plus-cellulite indication, filed under product code PBX. The newer Profound Matrix platform (K211217, and K240070 in 2024) is a different machine under product code GEI: its Matrix Pro applicator has 49 needles in a 7x7 grid reaching up to 3.5 mm, uses real-time impedance monitoring rather than temperature sensors, and is cleared for percutaneous treatment of facial wrinkles in Fitzpatrick skin types I to IV. It is not cleared for cellulite, and the cellulite trial does not belong to it.
If a clinic says "Profound", ask which one. The evidence, the feedback mechanism and the cleared indications are all different.
Five of the competitor devices covered here carry cosmetic wording in their cleared text: Vivace for facial wrinkles at 1 MHz in Fitzpatrick I to V, Virtue RF for facial wrinkles on its Smart RF handpiece at 1 MHz only, Profound for facial wrinkles and — on the SubQ handpiece in Fitzpatrick I to III — the appearance of cellulite, Profound Matrix for facial wrinkles in Fitzpatrick I to IV, and Alma Opus for ablation and resurfacing. Potenza, Secret RF, Genius, Sylfirm X, Scarlet, Agnes, PiXel8-RF and Exion's microneedling applicator have none — and neither does Morpheus8.
What that buys you is a smaller gap between what was reviewed and what is advertised. It does not buy you a better result, a longer-lasting one or a safer one. Those would need a trial comparing the devices, and no such trial exists.
It is also worth knowing that device-named published evidence is scarce across this whole category. Profound is one of only three devices in the set with PubMed-indexed studies naming the device. Most clinics quoting "studies" are quoting device-agnostic RF microneedling literature — and the longest properly measured follow-up anywhere in it is six months.
Profound's cellulite indication stops at Fitzpatrick III. Morpheus8's clearance restricts energies above 62 mJ per pin to skin types I to IV, so at higher settings deeper phototypes are outside the cleared labelling.
Radiofrequency heating does not depend on pigment the way light does, which is why this class is used across skin tones where ablative lasers are riskier — a split-face trial found fewer patches of darkened skin afterwards with RF microneedling than with fractional CO2 laser. Both facts are true at once. Ask what energy per pin is planned, ask for a test area, and expect conservative settings in deeper skin tones.
If you get cold sores, say so when you book — not on the day. Antiviral medicine is started in advance, so it has to be prescribed before the appointment. There is no published data on cold-sore reactivation after these treatments specifically; the precaution is carried over from laser resurfacing, where reactivation is well documented and prophylaxis is standard.
Also disclose a pacemaker or an implantable defibrillator, and any metal implant near the treatment area. These are labelled contraindications for radiofrequency devices generally. They are precautionary rather than tested — no published study has treated patients with cardiac implants — so the people to advise you are your cardiology team, not the clinic's front desk.
Say too if you have an active skin infection in the area, a history of raised or thickened scarring, or any current or past skin cancer where you are being treated.
These are signs of an infection that is spreading, and they need urgent care rather than a wait-and-see appointment.